GenSight Biologics S.A. (SIGHT.PA)
EUR 0.29
(-3.52%)
EUR 0.29
(-3.52%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.04 Million EUR | -89.74% |
| 2022 | 10.21 Million EUR | 42.79% |
| 2021 | 7.15 Million EUR | -37.69% |
| 2020 | 11.48 Million EUR | 76.83% |
| 2019 | 6.49 Million EUR | 88.75% |
| 2018 | 3.44 Million EUR | 13.45% |
| 2017 | 3.03 Million EUR | 3.78% |
| 2016 | 2.92 Million EUR | 369.7% |
| 2015 | 622.19 Thousand EUR | -1.6% |
| 2014 | 632.33 Thousand EUR | 0.0% |
| 2013 | - EUR | 0.0% |
| 2012 | - EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 15.45 Million EUR | 0.0% |
| 2024 Q1 | 15.45 Million EUR | 0.0% |
| 2023 Q4 | 1.04 Million EUR | -82.97% |
| 2023 FY | 1.04 Million EUR | -89.74% |
| 2023 Q3 | 6.15 Million EUR | 855.75% |
| 2023 Q1 | 5.99 Million EUR | -41.29% |
| 2023 Q2 | 644 Thousand EUR | -89.26% |
| 2022 Q2 | 4.71 Million EUR | -51.82% |
| 2022 Q3 | 15.43 Million EUR | 227.16% |
| 2022 Q1 | 9.79 Million EUR | 36.82% |
| 2022 Q4 | 10.21 Million EUR | -33.79% |
| 2022 FY | 10.21 Million EUR | 42.79% |
| 2021 Q1 | 13.69 Million EUR | 19.27% |
| 2021 Q3 | 12.09 Million EUR | 36.02% |
| 2021 Q2 | 8.89 Million EUR | -35.09% |
| 2021 FY | 7.15 Million EUR | -37.69% |
| 2021 Q4 | 7.15 Million EUR | -40.84% |
| 2020 Q3 | 16.16 Million EUR | 57.79% |
| 2020 Q2 | 10.24 Million EUR | -26.7% |
| 2020 FY | 11.48 Million EUR | 76.83% |
| 2020 Q1 | 13.97 Million EUR | 115.18% |
| 2020 Q4 | 11.48 Million EUR | -28.95% |
| 2019 Q3 | 9.77 Million EUR | 191.88% |
| 2019 Q4 | 6.49 Million EUR | -33.53% |
| 2019 FY | 6.49 Million EUR | 88.75% |
| 2019 Q1 | 6.88 Million EUR | 100.03% |
| 2019 Q2 | 3.34 Million EUR | -51.36% |
| 2018 Q3 | 3.44 Million EUR | 1.0% |
| 2018 Q4 | 3.44 Million EUR | 0.0% |
| 2018 FY | 3.44 Million EUR | 13.45% |
| 2018 Q1 | 3.4 Million EUR | 12.33% |
| 2018 Q2 | 3.4 Million EUR | 0.0% |
| 2017 Q3 | 3.03 Million EUR | 12.29% |
| 2017 Q4 | 3.03 Million EUR | 0.0% |
| 2017 Q1 | 2.7 Million EUR | -7.58% |
| 2017 Q2 | 2.7 Million EUR | 0.0% |
| 2017 FY | 3.03 Million EUR | 3.78% |
| 2016 Q1 | - EUR | -100.0% |
| 2016 FY | 2.92 Million EUR | 369.7% |
| 2016 Q4 | 2.92 Million EUR | 0.02% |
| 2016 Q3 | 2.92 Million EUR | 0.0% |
| 2015 Q3 | 622.19 Thousand EUR | -2.09% |
| 2015 Q1 | 635.49 Thousand EUR | 0.5% |
| 2015 FY | 622.19 Thousand EUR | -1.6% |
| 2015 Q2 | 635.49 Thousand EUR | 0.0% |
| 2015 Q4 | 622.19 Thousand EUR | 0.0% |
| 2014 FY | 632.33 Thousand EUR | 0.0% |
| 2014 Q4 | 632.33 Thousand EUR | 0.0% |
| 2014 Q3 | 632.33 Thousand EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2013 FY | - EUR | 0.0% |
| 2012 FY | - EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | 4.814% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 97.655% |
| Adocia SA | 4.54 Million EUR | 76.916% |
| Aelis Farma SA | 2.04 Million EUR | 48.828% |
| Biophytis S.A. | 3.11 Million EUR | 66.313% |
| Advicenne S.A. | 15.89 Million EUR | 93.407% |
| genOway Société anonyme | 5.51 Million EUR | 81.012% |
| IntegraGen SA | 642.28 Thousand EUR | -63.169% |
| Medesis Pharma S.A. | 1.2 Million EUR | 12.667% |
| Neovacs S.A. | 650 Thousand EUR | -61.231% |
| NFL Biosciences SA | 39.2 Thousand EUR | -2573.265% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 75.944% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | 46.54% |
| Sensorion SA | 1.24 Million EUR | 15.546% |
| Theranexus Société Anonyme | 2.46 Million EUR | 57.411% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | 73.114% |
| TheraVet SA | 1 Million EUR | -4.737% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | 84.825% |
| argenx SE | 15.35 Million EUR | 93.174% |
| BioSenic S.A. | 15.57 Million EUR | 93.27% |
| Celyad Oncology SA | 902 Thousand EUR | -16.186% |
| DBV Technologies S.A. | 4.52 Million USD | 76.845% |
| Galapagos NV | 4.94 Million EUR | 78.803% |
| Genfit S.A. | 62.25 Million EUR | 98.317% |
| GeNeuro SA | 6.49 Million EUR | 83.858% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -204.651% |
| Innate Pharma S.A. | 30.6 Million EUR | 96.576% |
| Inventiva S.A. | 25.61 Million EUR | 95.909% |
| MaaT Pharma SA | 5.42 Million EUR | 80.682% |
| MedinCell S.A. | 52.8 Million EUR | 98.015% |
| Nanobiotix S.A. | 41.66 Million EUR | 97.484% |
| Onward Medical N.V. | 16.3 Million EUR | 93.573% |
| Oryzon Genomics S.A. | 3.45 Million EUR | 69.629% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | 97.049% |
| Oxurion NV | 117 Thousand EUR | -795.726% |
| Pharming Group N.V. | 123.65 Million EUR | 99.152% |
| Poxel S.A. | 40.14 Million EUR | 97.389% |
| Transgene SA | 17 Thousand EUR | -6064.706% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 99.964% |
| Valneva SE | 132.76 Million EUR | 99.211% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |